pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
235
stories
14d
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
endpoints
14d
Recon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deaths
raps
14d
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
15d
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
15d
A winner, a loser, and a mid-stage signal from a major cardiology research conference
stat
15d
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
15d
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
17d
STAT+: A Novartis drug cut inflammation. Can it improve heart outcomes?
stat
17d
#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo's failure
endpoints
19d
A year on from Big Pharma’s pull-back from the UK, has anything changed?
fiercebiotech
20d
Flagship’s ProFound partners with Gates Foundation in $35M preeclampsia target discovery pact
fiercebiotech
20d
Research into protein interactions sheds new light on causes of autism
fiercebiotech
20d
STAT+: New treatments for common cardiovascular risk factor near the market, with billions at stake
stat
21d
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency
biospace
22d
News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026
endpoints
25d
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
26d
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
26d
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
26d
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
26d
7 biopharma M&A deals where layoffs followed
biospace
28d
BioMarin acquires experimental drug for rare bone disorder in $275M deal
biopharma dive
28d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
28d
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
stat
29d
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
29d
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
biospace
Aug 14, 26
STAT+: PBMs agree to display TrumpRx drug prices
stat
Aug 13, 26
July's biopharma layoffs affect 466 employees, a 94% year-over-year drop
biospace
Aug 12, 26
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
Aug 12, 26
STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
stat
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
← prev
page 4 of 8
next →
